Investigating the potential role of TRPA1 in locomotion and cardiovascular control during hypertension. by Bodkin, JV et al.
Investigating the potential role of TRPA1 in locomotion and cardiovascular
control during hypertension.
Bodkin, JV; Thakore, P; Aubdool, AA; Liang, L; Fernandes, ES; Nandi, M; Spina, D; Clark,
JE; Aaronson, PI; Shattock, MJ; Brain, SD
 
 
 
 
 
© 2014 The Authors.
CC-BY
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/xmlui/handle/123456789/15222
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
ORIGINAL ARTICLE
Investigating the potential role of TRPA1 in locomotion
and cardiovascular control during hypertension
Jennifer V. Bodkin1, Pratish Thakore1,2, Aisah A. Aubdool1, Lihuan Liang1, Elizabeth S. Fernandes1,3,
Manasi Nandi2, Domenico Spina2, James E. Clark1, Philip I. Aaronson4, Michael J. Shattock1 & Susan
D. Brain1
1Cardiovascular Division, BHF Centre of Excellence and Centre of Integrative Biomedicine, School of Medicine, King’s College London, London,
SE1 9NH, U.K.
2Pharmaceutical Sciences Division, School of Biomedical Sciences, King’s College London, London, SE1 9NH, U.K.
3Programa de Pos-Graduac~ao em Biologia Parasitaria, Universidade Ceuma, S~ao Luıs, Brazil
4Asthma, Allergy and Lung Biology Division, School of Medicine, King’s College London, London, SE1 1UL, U.K.
Keywords
Blood pressure, cinnamaldehyde,
hypertension, locomotion, TRPA1
Correspondence
Susan D. Brain, BHF Centre of Excellence and
Centre of Integrative Biomedicine,
Cardiovascular Division, School of Medicine,
King’s College London, Franklin-Wilkins
Building, 150 Stamford Street, London, SE1
9NH, United Kingdom. Tel: 020 7848 4453;
E-mail: sue.brain@kcl.ac.uk
Funding Information
This study was supported by the British Heart
Foundation (J. V. B., P. T., M. N., M. J. S.), a
capacity building award in Integrative
Mammalian Biology funded by the BBSRC,
BPS, HEFCE, KTN, MRC, and SFC (A. A. A., L.
L., S. D. B.) and Arthritis Research UK (E. S. F.).
Received: 17 February 2014; Revised: 23
April 2014; Accepted: 24 April 2014
Pharma Res Per, 2(4), 2014, e00052,
doi: 10.1002/prp2.52
doi: 10.1002/prp2.52
Abstract
Radiotelemetry was used to investigate the in vivo cardiovascular and activity
phenotype of both TRPA1 (transient receptor potential ankyrin 1) wild-type
(WT) and TRPA1 knockout (KO) mice. After baseline recording, experimental
hypertension was induced using angiotensin II infusion (1.1 mg1 kg1 a day,
for 14 days). TRPA1 WT and KO mice showed similar morphological and
functional cardiovascular parameters, including similar basal blood pressure
(BP), heart rate, size, and function. Similar hypertension was also displayed in
response to angiotensin II (156  7 and 165  11 mmHg, systolic BP  SEM,
n = 5–6). TRPA1 KO mice showed increased hypertensive hypertrophy (heart
weight:tibia length: 7.3  1.6 mg mm1 vs. 8.8  1.7 mg mm1) and pre-
sented with blunted interleukin 6 (IL-6) production compared with hyperten-
sive WT mice (151  24 vs. 89  16 pg mL1). TRPA1 expression in dorsal
root ganglion (DRG) neurones was upregulated during hypertension (163% of
baseline expression). Investigations utilizing the TRPA1 agonist cinnamalde-
hyde (CA) on mesenteric arterioles isolated from n€aive mice suggested a lack
of TRPA1-dependent vasoreactivity in this vascular bed; a site with notable
ability to alter total peripheral resistance. However, mesenteric arterioles iso-
lated from TRPA1 KO hypertensive mice displayed significantly reduced ability
to relax in response to nitric oxide (NO) (P < 0.05). Unexpectedly, na€ıve
TRPA1 KO mice also displayed physical hyperactivity traits at baseline, which
was exacerbated during hypertension. In conclusion, our study provides a
novel cardiovascular characterization of TRPA1 KO mice in a model of hyper-
tension. Results suggest that TRPA1 has a limited role in global cardiovascular
control, but we demonstrate an unexpected capacity for TRPA1 to regulate
physical activity.
Abbreviations
ADHD, attention-deficit/hyperactivity disorder; ANOVA, analysis of variance; BP,
blood pressure; BW, body weight; CA, cinnamaldehyde; cDNA, complementary
DNA; CGRP, calcitonin gene-related peptide; CO, cardiac output mL/min; DMSO,
dimethyl sulfoxide; DRG, dorsal root ganglion; EF, ejection fraction %; ELISA,
enzyme-linked immunosorbent assay; FS, fractional shortening %; GAPDH, glycer-
aldehyde-3-phosphate dehydrogenase; HIF1a, hypoxia-inducible factor 1 alpha;
IFNc, interferon gamma; IL, interleukin; IVS, interventricular septum at diastole;
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KC, mouse KC/CXCL1; KO, knockout; LVAW, left ventricular anterior wall at
diastole; LV, left ventricle; LVPW, left ventricular posterior wall at diastole; mRNA,
messenger ribonucleic acid; NfjB, nuclear factor kappa B; NO, nitric oxide; PCR,
polymerase chain reaction; PLA2G12A, phospholipase A2; qPCR, quantitative poly-
merase chain reaction; RNA, ribonucleic acid; RTPCR, reverse transcription poly-
merase chain reaction; SEM, standard error of the mean; SNP, sodium
nitroprusside; SV, stroke volume; TNFa, tumor necrosis factor alpha; TRPA1, tran-
sient receptor potential ankyrin 1; TxA2, thromboxane A2; WT, wild type.
Introduction
The transient receptor potential ankyrin 1 (TRPA1)
receptor is activated by a range of potentially injurious
exogenous and endogenous compounds, leading to the
release of neuropeptides (Bodkin and Brain 2010; Earley
2012). Since its identification it has developed a signifi-
cant reputation as a mediator of pain and inflammation
(Jaquemar et al. 1999). TRPA1 is classically expressed on
C-fiber sensory neurones (Story et al. 2003), but expres-
sion in other locations has been reported, including rat
cerebral artery endothelial cells (Earley et al. 2009). In
line with the role for TRPA1 in inflammation, several
groups demonstrate TRPA1 agonists to cause vasorelax-
ation or vasodilation, occurring in a range of species and
vascular beds (Bodkin and Brain 2010). TRPA1-induced
vasorelaxation is commonly identified to be neuropeptide
mediated (Louis et al. 1989; Morris et al. 1999; Hikiji
et al. 2000; Grant et al. 2005; Namer et al. 2005; Graepel
et al. 2011; Kunkler et al. 2011), while other studies pro-
pose direct changes in calcium handling (Yanaga et al.
2006; Earley et al. 2009; Xue et al. 2011).
Cinnamaldehyde (CA) is a commonly used TRPA1
agonist, selected due to its relative selectivity and potency
(Bandell et al. 2004). It has been shown to cause vasore-
laxation and vasodilation in several studies (VanderEnde
and Morrow 2001; Namer et al. 2005; Yanaga et al. 2006;
Pozsgai et al. 2010; Xue et al. 2011). Our group has also
recently demonstrated CA induced ex vivo vasorelaxation
and in vivo vasodilation responses to be significantly
reduced in TRPA1 knockout (KO) mice (Pozsgai et al.
2010). Moreover, intravenous administration of CA initi-
ated an autonomic vaso-vagal response which significantly
reduced in TRPA1 KO mice (Pozsgai et al. 2010). Similar
blood pressure (BP) reflexes have previously been
observed in other species following systemic administra-
tion of CA (Harada et al. 1975, 1982), alongside changes
in autonomic drive and heart rate (Iwasaki et al. 2008;
Hazari et al. 2011).
Our group has recently demonstrated the protective
role of the neuropeptide calcitonin gene-related peptide
(CGRP) in hypertension (Smillie et al. 2014), so we
hypothesized that TRPA1 KO mice may show suscepti-
bility to angiotensin II-induced hypertension and related
morbidities. Basal and hypertensive cardiovascular charac-
teristics were generally similar in TRPA1 (wild-type) WT
and KO mice. However, some significant differences were
seen in TRPA1 KO mice during hypertension; notably, a
trend for increased hypertrophy and a blunted increase
in IL-6. Little difference in the pharmacology of mesen-
teric arterioles from either genotype was seen. Our most
surprising and striking finding was that TRPA1 KO mice
demonstrated a previously undescribed hyperactivity
trait.
Materials and Methods
Animals
Experiments were carried out according to the Animals
(Scientific Procedures) Act 1986 and were ethically
approved by the local Research Ethics Committee. Ani-
mals were bred and housed in a climatically controlled
environment, on a 12-h light (7 AM–7 PM)/dark cycle,
with free access to a normal diet and water. Initial pairs
of mixed genetic background TRPA1 WT and KO mice
(C57BL/6B6129P1/F2J) were as described in Pozsgai
et al. (2010). Both sexes of mice were used in pairs,
aged between 2 and 3 months, and weighing more than
20 g. Mice were age matched and also littermates where
possible. Appropriate handling and care was taken
throughout, with postsurgical analgesia provided. The
number of animals used per experiment is stated in
each figure.
Wire myography
First-order mesenteric artery branches (~150–250 lm
diameter) were isolated from CD1, TRPA1 WT, or TRPA1
KO mice in ice-cold-modified Krebs’-Henseleit solution
(118 mmol/L NaCl, 24 mmol/L NaHCO3, 1 mmol/L
MgSO4, 4 mmol/L KCl, 0.5 mmol/L NaH2PO4, 5.5 mmol/
L glucose, and 2.5 mmol/L CaCl2, all salts from Sigma-
Aldrich, Gillingham, U.K.). They were cleansed of fatty tis-
sue, mounted, and normalized to normal peripheral artery
tension (13.3 kPa) on a wire myograph (DMT 610M or
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620) using 0.025-mm stainless steel wires, as in Pozsgai
et al. (2010). Vessels were maintained throughout the
experiment in 37°C Krebs gassed with air/5% CO2. Vessel
viability was assessed by determining constriction to
80 mmol/L K+ Krebs’ solution (reduction of NaCl to
38 mmol/L, all other constituents remain unchanged), and
endothelial function was assessed using carbachol
(10 lmol/L, in double deionized water, Sigma-Aldrich),
where a relaxation of >60% was used as a positive thresh-
old. Cumulative concentration-response curves were
constructed to the a1-adrenergic receptor agonist phenyl-
ephrine (30 nmol/L to 100 lmol/L in double deionized
water, Sigma-Aldrich) and the thromboxane A2 (TxA2)
analogue, U46619 (100 pmol/L to 300 nmol/L, ethanol in
double deionized water; Enzo Life Sciences, Exeter, U.K.).
Data are expressed as percentage of 80 mmol/L K+ Krebs’-
induced contraction. For relaxation studies, tissues were
submaximally preconstricted with U46619 (10 nmol/L),
then exposed to cumulative additions of either CA (trans-
cinnamaldehyde >95%, Sigma-Aldrich, 3–1000 lmol/L,
ethanol), human aCGRP (1–300 nmol/L in 0.01% bovine
serum albumin [BSA], double deionized water, Bachem,
Bubendorf, Switzerland), carbachol (100 pmol/L to
30 lmol/L in double deionized water, Sigma-Aldrich), or
sodium nitroprusside ([SNP],100 pmol/L to 30 lmol/L in
double deionized water, Sigma-Aldrich). Data are
expressed as percentage relaxation of preconstricted tone.
In some experiments, additional pharmacological tools
were used, this included the CGRP receptor antagonist
CGRP8-37 (3 lmol/L in 0.01% BSA in double deionized
water, 5 min before preconstriction; Bachem) and the
TRPA1 antagonist HC030031 (50 lmol/L in dimethyl sulf-
oxide [DMSO] and Krebs), 15 min before preconstriction;
Tocris Bioscience, Bristol, U.K.). Results from multiple
vessels per mouse were averaged to produce each N. A four
parameter logistic equation enabled us to plot response
curves, where EMax and pEC50 values were extrapolated
and analyzed to determine statistical significance (Graph-
Pad Prism 5, GraphPad Software Inc., La Jolla, CA).
Radiotelemetry
BP, heart rate, and spontaneous activity counts were mea-
sured using a telemetry device (PA-C10, DSI, NL), with
the catheter tip placed in the left carotid artery and
advanced toward the aortic arch. The transmitter body
was placed subcutaneously in the right flank, similar to
Marshall et al. (2013). Implantation surgery was con-
ducted using aseptic techniques under a surgical level of
isoflurane anesthesia (Abbott Laboratories, Maidenhead,
U.K.). Pain relief was administered before the procedure
in the form of intramuscular buprenorphine (50 lg kg1,
Vetergesic). Baseline data were collected at days 10–13
post surgery using DSI software (DSI Dataquest A.R.T.,
Data Sciences International, s’Hertogenbosch, the Nether-
lands).
Experimental hypertension
On day 14 post telemetry surgery, induction of experi-
mental hypertension was initiated with 14-day continuous
infusion of angiotensin II (1.1 mg1 kg1 per day,
Sigma-Aldrich) by subcutaneously implanted osmotic
minipump (1002; Alzet, Cupertino, CA), with control
mice also receiving a pump, as in Smillie et al. (2014).
Telemetered animals were monitored for hypertension
progression immediately following implantation for
14 days. Mice were then terminated, 100-lL aliquots of
plasma were snap frozen, and stored at 80°C. DRG,
heart, mesenteric arteries, lower aorta portion, and brain
segments were individually stored in RNA later (Sigma-
Aldrich), as per manufacturer’s instructions. Mesenteric
arterioles were also collected and examined for pharmaco-
logical changes using myography.
Voluntary wheel running
Mixed genotype littermate mice (2 months of age) had
plastic wheels (13.4 cm diameter) added to their home
cage for acclimatization. After 3 weeks, mice pairs were
separated by genotype and moved to a quiet room. Daily
running (km) and speed of wheel turning (km h1) were
recorded using a rotational counter for a period of
7 days/6 nights. No significant differences in activity
between male and female mice were observed.
Echocardiography
Ventricular mass, wall thicknesses, and functional mea-
surements were collected from 3-month-old mice, either
na€ıve or telemetered animals (both preimplantation of
osmotic minipumps and at the end of 14-day angiotensin
II infusion). Cardiac echocardiography was performed
using a VEVO 770 with a mouse scan head (RMV 707B,
30 Hz; VisualSonics, Inc., Toronto, ON, Canada), carried
out as in Respress and Wehrens (2010). The examination
lasted less than 20 min. M-mode and B-mode images were
analyzed using the leading edge to leading edge method
over five sinus beats. Ventricle mass and thicknesses are
expressed as ratio to mouse body mass, whereas functional
measures are expressed in their respective units.
Plasma cytokine quantification
Interleukin 1 (IL-1), tumor necrosis factor alpha
(TNFa), Interleukin 12 (IL-12), murine Interleukin 8
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(KC), interferon gamma (IFNc), Interleukin 10 (IL-10),
and IL-6 plasma protein levels were measured (Russell
et al. 2009), using a seven spot multiplex mouse pro-
inflammatory assay kit (Meso-Scale Discovery, Gaithers-
burg, MD).
Real-time reverse transcription polymerase
chain reaction
Real-time reverse transcription polymerase chain reaction
(RT-qPCR) was carried out as in Smillie et al. (2014).
Total ribonucleic acid (RNA) was extracted from tissue
using the Qiagen RNeasy Microarray tissue mini Kit
(Qiagen, Manchester, U.K.) and Qiagen’s TissueLyser LT.
A Reverse transcription enzyme kit with RNAase inhibitor
(Life Technologies, Paisley, U.K.) and thermal cycler (Life
Technologies) was used for reverse transcription to com-
plementary DNA (cDNA). Quantitative PCR (qPCR) was
then conducted using a SYBR-green-based PCR mix
(Sensi-Mix, SYBR-green No ROX; Bioline Reagents Ltd.,
London, U.K.) pipetted into 100-well gene disks (Qiagen)
by an automated robot (CAS1200; Qiagen Corbett,
Manchester, U.K.), followed by PCR in a Corbett Rotor-
gene 6000. Settings were as follows; hold: 10 min at 95°C;
cycling: 45 cycles: 10 sec at 95°C, 15 sec at 57°C, and
5 sec at 72°C; melt: 68–90°C. Data were collected as cop-
ies/lL and normalized against murine phospholipase A2
(PLA2G12A), actin, and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) expression using GeNorm3.4 soft-
ware (Vandesompele et al. 2002). The following primers
were from Sigma-Aldrich (50–30): TRPA1: F-AGGTGA
TTTTTAAAACATTGCTGAG, R-CTCGATAATTGATGTC
TCCTAGCAT; IL-6: F-GCTACCAAACTGGATATAATCA
GGA, R- CCAGGTAGCTATGGTACTCCAGAA; PLA2G12A:
F-TGGATATAAACCATCTACCA, R-GGGAAGGGATACC
TATGTTCAGA; Actin: F-CACAGCTTCTTTGCAGCTCC
TT, R-TCAGGATACCTCTCTTGCTCT; GAPDH: F- GGT
CATCCCAGAGCTGAACG, R- TTGCTGTTGAAGTCGC
AGGA.
Data analysis
Data are shown as mean  standard error of the mean
(SEM). Data are presented and tested for significance
using GraphPad Prism 5. Multiple group analysis was
performed by one- or two-way analysis of variance
(ANOVA) with Sidak’s or Bonferroni’s post hoc test, or a
two-tailed unpaired t-test for two groups. For nonpara-
metric datasets, a Mann–Whitney U-test was used. A one-
tailed unpaired t-test was used to compare TRPA1 WT
and KO spontaneous activity levels in the final week of
angiotensin II infusion. Statistical tests and outcomes are
described within each figure legend.
Results
Na€ıve TRPA1 WT and KO mice display
indistinguishable cardiovascular phenotypes
We previously reported similar baseline BP and heart rate
values in anesthetized TRPA1 WT and KO mice (Pozsgai
et al. 2010). We now confirm these findings using radio-
telemetry from conscious, unrestrained TRPA1 WT and
KO mice (Fig. 1). Averaged from three consecutive days
and plotted half hourly, TRPA1 KO mice showed similar
systolic, mean, and diastolic BP profiles (Fig. 1A–C).
These similarities were also reflected in the 24-h averages
shown in panels D–F. The heart rate profile and 24-h
average were also similar between TRPA1 WT and KO
mice (Fig. 1G–H). Clear diurnal rhythms were seen
within the data, showing peaks in BP and heart rate
shortly after switch-over to darkness; a pattern expected
from nocturnal animals.
Telemetered and na€ıve mice were assessed for cardiac
morphology and function in vivo using echocardiography.
Table 1 comprises some key measures, namely body
weight (BW), left ventricle (LV) mass, cardiac output
(CO), stroke volume (SV), ejection fraction (EF), and
fractional shortening (FS); which were found to be almost
identical in TRPA1 WT and KO mice. Ventricular wall
thicknesses were also assessed, and were indistinguishable
(WT data are shown in Fig. 4C). These findings were
confirmed by measuring heart mass at necropsy, where
ratios to BW and tibia length showed heart mass to be
similar in WT and KO mice (Table 1).
Na€ıve TRPA1 KO mice display
an unexpectedly increased preference
for activity when compared with TRPA1
WT littermates
The PA-C10 telemetry probe also measures spontaneous
activity counts, collected in parallel with BP measure-
ments. Figure 2A shows the profile of activity counts,
averaged over 3 days of recording, and plotted every half
an hour. Figure 2B shows the average number of counts
over 24 h. TRPA1 KO mice participated in increased
spontaneous activity compared to TRPA1 WT mice. Data
was split to show activity counts collected during the light
and dark phases (Fig. 2C), where the majority of activity
occurred during the nighttime. This showed that TRPA1
KO mice did not participate in more prolonged activity
(i.e., disturbed sleep), but moved about more intensely
during waking hours. In order to address the potential
effect of activity on cardiovascular parameters, average
blood pressures collected during the peak of activity (8–
8.30 PM) were plotted (Fig. 2D). TRPA1 WT and KO
2014 | Vol. 2 | Iss. 4 | e00052
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mice showed no significant differences in BP despite clear
differences in activity levels.
To investigate this further, pairs of na€ıve mice were
allowed free access to a running wheel in their cage. After
3 weeks of acclimatization, mice were moved to a
secluded room and their running behavior measured
remotely. Figure 2E shows a histogram of wheel turning
speeds and the mode of preferred running speed, derived
from this, is shown in Figure 2F. Consistent with indica-
tions from telemetered animals, TRPA1 KO mice showed
a preference for running at faster speeds than their WT
littermates, therefore conducted more intense periods of
voluntary activity. This is reflected in the average daily
distance and the total weekly distance ran by mouse pairs
(Fig. 2G–H). Therefore, our findings show that when
given the opportunity to exercise, TRPA1 KO mice pre-
ferred to run further, and faster than TRPA1 WT mice.
TRPA1 WT and KO mice show similar
hypertension following angiotensin II
infusion, while activity levels are further
exacerbated in TRPA1 KO mice
TRPA1 KO mice were infused with a pressor dose of angio-
tensin II for 14 days (1.1 mg1 kg1 day), similar to that
used in Smillie et al. (2014). Figure 3A shows the profile of
hypertension onset, in terms of systolic BP and heart rate,
plotted as 4-h averages. Basal data are also shown for com-
parison. Hypertension was established within the first few
days of angiotensin II infusion, with onset and magnitude
being similar in TRPA1 WT and KO mice. No changes in
heart rate were observed over this period (Fig. 3A). Average
24-h systolic BP was significantly elevated after 14 days of
angiotensin II infusion in TRPA1 WT and KO mice, but
with similar magnitudes (Fig. 3B).
0
200
400
600
800
(A) (B) (C)
(D)
(G) (H)
(E) (F)
Figure 1. Basal hemodynamics in TRPA1 WT and KO mice measured by telemetry. Systolic, mean, and diastolic pressure (A–C) with heart rate
(G) readings were collected 10–13 days after implantation of telemetry probe PA-C10 with an aortic arch placed catheter. Mice experience a 12/
12 h light/dark cycle, with the dark cycle shown in the shaded area. Data are shown as hourly averages collected from three daily cycles. (D–H)
show respective datasets shown as 24-h averages. N = 7–10 mice for all, data shown  SEM. Groups are not significantly different when tested
with appropriate statistical analysis.
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Despite similar BP responses in TRPA1 WT and KO
mice, the differences in spontaneous activity levels were
exacerbated during angiotensin II infusion. Spontaneous
activity counts were concomitantly measured with BP and
are shown in Figure 3C. After an initial reduction in activ-
ity following surgery, TRPA1 KO mice reaffirmed trends
for increased activity compared to WT mice. Furthermore,
as the infusion period progressed, TRPA1 WT mice showed
little change in activity level, whereas TRPA1 KO mice
showed an ever-increasing amount of activity. This data is
summarized in Figure 3D and F, consistently showing
trends for increased activity levels in TRPA1 KO mice. The
magnitude of these differences was increased during the
final infusion day (Fig. 3D) and spontaneous activity levels
during the second week of angiotensin II infusion were sig-
nificantly higher in TRPA1 KO mice compared to WT mice
(Fig. 3F). When 14-day activity profiles were separated to
show activity counts occurring in the light and dark phases,
TRPA1 KO mice displayed higher levels of nocturnal activity
(Fig. 3E). In keeping with previous data, TRPA1 KO mice
showed more intense nocturnal activity than WT mice,
which was further enhanced during angiotensin II infusion.
TRPA1 KO mice show a trend for increased
hypertrophy and significant blunting in the
production of IL-6 despite a broadly similar
hypertensive response
TRPA1 activation has strong links to inflammation. We
have recently shown genetic KO mice and receptor antag-
onists to reduce the hyperalgesia response in a murine
model of joint inflammation (Fernandes et al., 2011).
Hypertension, particularly that induced by overstimula-
tion of the renin-angiotensin system, possesses a large
inflammatory component (Savoia and Schiffrin 2006).
Therefore, we investigated pathology in our hypertensive
TRPA1 WT and KO mice.
BW in TRPA1 WT and KO mice after 14 days of
hypertension was similar (Fig. 4A). Heart mass-to-body
mass ratios were significantly increased at day 14
compared to baseline values for both groups (Table 2).
However, heart weight-to-tibia length (Fig. 4B) and LV
mass-to-body mass (Table 2) ratios both showed TRPA1
KO mice to develop significantly more cardiac hypertro-
phy than TRPA1 WT mice. Left ventricular mass and wall
thicknesses were measured using in vivo echocardiogra-
phy at day 14 of angiotensin II infusion, along with func-
tional measures. These showed further trends for
increased ventricular wall thicknesses and a significantly
increased left ventricular mass in hypertensive TRPA1 KO
mice compared to hypertensive WT mice. In spite of these
differences, cardiac function was not significantly different
between genotypes (Fig. 4C, Table 2).
IL-6 is an important cytokine in angiotensin II-induced
hypertension, where the magnitude of BP increase is signif-
icantly reduced in IL-6 KO mice (Lee et al. 2006). Direct
IL-6 infusion mediates cardiac fibrosis, resulting in diastolic
dysfunction (Melendez et al. 2010). IL-6 is also a “myokine,”
produced by skeletal muscles during exercise and has
important endocrine functions (Pedersen and Febbraio
2008). We measured plasma protein concentrations of IL-6
and messenger ribonucleic acid (mRNA) expression in the
heart and aorta (Fig. 5A–C). In all cases, IL-6 was strongly
upregulated during angiotensin II infusion in TRPA1 WT
mice. This effect was far weaker in angiotensin II-treated
TRPA1 KO mice, which showed significantly less IL-6 in
plasma and mRNA expression in the heart compared to
angiotensin II-treated WT mice. Similar patterns were seen
in plasma IL-6 levels and aortic mRNA expression. This
effect was specific to IL-6 as the plasma level of several
other cytokines was not significantly different between
angiotensin II-treated TRPA1 WT and KO mice (Table 3).
Low levels of TRPA1 mRNA expression
are found in tissues of the circulatory
system and brain, but predominant
expression is found in DRG, where it
is upregulated in hypertension
TRPA1 gene expression is upregulated following chemical
or physical nerve injury (Frederick et al. 2007). High lev-
els of TRPA1 mRNA were found in DRG neurones from
TRPA1 WT mice, with significantly elevated expression
Table 1. Basal body weight, heart size, and function in TRPA1 WT
and KO mice.
TRPA1 WT TRPA1 KO
Body weight
(g)
24.34  1.00
N = 27
25.17  0.93
N = 27
HW:BW
(mg)
4.69  0.18
N = 11
4.87  0.20
N = 13
HW:Tibia length
(lg mm1)
67.79  6.21
N = 8
73.02  4.71
N = 9
LV:BW
(mg g1)
(echocardiography)
4.23  0.22
N = 27
4.32  0.24
N = 29
Cardiac output
(mL min1)
17.27  0.93
N = 27
17.14  0.93
N = 29
Stroke volume
(lL)
34.44  1.68
N = 27
35.20  1.54
N = 29
Ejection fraction
(%)
66.73  1.76
N = 27
64.59  1.57
N = 29
Fractional shortening
(%)
35.67  1.36
N = 27
34.08  1.07
N = 29
Total body mass (BW), heart mass (HW), and tibia length were mea-
sured in 3-month-old mice at necropsy, while LV mass-to-body weight
ratio (LV:BW) and all functional measures were previously calculated
using in vivo echocardiography. Units and N as indicated  SEM.
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following 14 days of angiotensin II infusion (Fig. 6A).
Lower copy numbers were found in tissues from several
areas of the circulatory system, namely, heart, aorta, and
mesenteric arterioles, where expression was not altered by
angiotensin II infusion (Fig. 6B). Due to our novel find-
ings of physical activity differences in TRPA1 WT and
KO mice, we additionally investigated expression of
TRPA1 in several brain areas related to locomotion con-
trol. Low levels of TRPA1 expression were found in the
medulla, cortex, and striatum, with no alterations follow-
ing angiotensin II infusion (Fig. 6C).
CA-induced vasorelaxation is not dependant
on TRPA1 or CGRP
CA is a well-accepted TRPA1 agonist which induces
vasorelaxation that is often mediated by neuropeptide
release (Louis et al. 1989; Morris et al. 1999; Hikiji et al.
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were collected by telemetry on days 10–13 following implantation of a PA-C10 probe and presented as half hourly (A) and 24-hourly (B) averages,
and also as averages during the 12-h light and dark phases (C). Corresponding BP data were collected from a catheter in the aortic arch and average
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in pairs were allowed access to an activity wheel. After a 2-week acclimatization period, mice were moved to a secluded room and data on wheel
usage were collected over a 6-night/7-day period. (E) shows a histogram of wheel turning speed and (F) shows the mode of these data, describing the
preferred running speed of the littermate mouse pairs. G and H show the average distance ran per day and the total distance ran over the experimental
period. N = 6 WT pairs, 4 KO pairs. All data shown  SEM. Statistics in C are from one-way ANOVA with Sidak’s post hoc test, *P < 0.05 or
**P < 0.01 compared to respective light-time count. Statistics G and H are from a nonparametric, one-tailed Mann–Whitney U-test. *P < 0.05.
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2000; Grant et al. 2005; Namer et al. 2005; Graepel et al.
2011; Kunkler et al. 2011; Pozsgai et al. 2012). We have
previously shown CA to cause in vivo vasodilation in the
mouse paw and ex vivo vasorelaxation of mouse mesen-
teric arteries, both responses which were significantly
reduced in TRPA1 KO mice/tissues (Pozsgai et al. 2010).
Following on from our findings in this current study,
showing low expression of TRPA1 in mesenteric arteri-
oles, we have reevaluated and repeated our previous
experiment investigating CA-induced relaxation of TRPA1
WT and KO mesenteric arteries, preconstricted in
response to the TxA2 analogue U46619. Similar to our
previous report, the contractile responses to U46619 were
identical in TRPA1 WT and KO mesenteric arteries, both
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Figure 3. Hemodynamic and locomotion characteristics in TRPA1 WT and KO mice during 14 days of angiotensin II infusion, measured by
telemetry. Angiotensin II was infused at 1.1 mg kg1 a day from a subcutaneously implanted osmotic minipump. BP and activity counts were
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infusion. N = 7–10 mice, all data shown  SEM. Statistics in B and D are from a two-way ANOVA, with Sidak’s post hoc test. **P < 0.01. ***
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with and without functional endothelium (Data not
shown). CA induced dose-dependent vasorelaxation of
WT mesenteric arteries, which occurred independently of
the endothelium (Fig. 7A). However, during this study
we could not clearly demonstrate a TRPA1-dependent
component using the TRPA1 antagonist HC030031 or
vessels from TRPA1 KO mice (Fig. 7B–D).
TRPA1 is predominantly localized to sensory C
fibers which release neuropeptides, including the potent
vasodilator CGRP, when activated. We investigated the
dependence of CA responses on CGRP. In Figure 7E, we
show the CGRP peptide antagonist, CGRP8-37, to reduce
aCGRP-induced vasorelaxation equally in TRPA1 WT
and KO mesenteric arteries. This demonstrates the effi-
cacy of the antagonist and also the lack of compensatory
changes toward CGRP in TRPA1 KO tissues. However,
CGRP8-37 did not alter the potency of CA-induced
vasorelaxation in TRPA1 WT or KO arteries (Fig. 7F),
providing evidence that the CA response is not CGRP
mediated in mesenteric arterioles.
Table 2. Cardiac mass and function in TRPA1 WT and KO mice fol-
lowing 14-day infusion of angiotensin II.
14-day angiotensin II
TRPA1 WT TRPA1 KO
HW:BW
(mg)
5.61  0.21*
N = 18
6.19  0.23*
N = 22
LV:BW
(mg g1)
(echocardiography)
5.26  0.19
N = 10
5.79  0.38*
N = 13
Cardiac output
(mL min1)
14.47  1.47
N = 8
13.25  0.92
N = 10
Stroke volume
(lL)
30.35  2.44
N = 7
26.16  1.80
N = 10
Ejection fraction
(%)
54.06  2.28
N = 8
60.48  3.53
N = 10
Fractional shortening
(%)
27.44  1.45
N = 8
32.07  2.75
N = 10
Heart weight (HW) and body weight (BW) were calculated at necropsy.
All other measures were collected using in vivo echocardiography,
including left ventricular mass (LV). N as indicated, data shown  SEM.
*P < 0.05 compared to previously quoted basal values (Table 1) using
a two-way ANOVA with Sidak’s post hoc test.
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Figure 4. Body weight, cardiac mass, and thickness in TRPA1 WT and KO mice following 14-day infusion of angiotensin II. Body weight (A),
heart weight, and tibia length were calculated at necropsy following 14 days of angiotensin II infusion (1.1 mg kg1 a day) via a subcutaneously
implanted osmotic minipump. Heart weight:tibia length ratio is shown in B. Thicknesses of the interventricular septum (IVS), and the left ventricle
anterior (LVAW) and posterior (LVPW) walls were measured before termination using in vivo echocardiography, and are expressed as a ratio to
body weight (C). N = 18 mice in A and B, 10–12 mice in C. Data shown  SEM and statistics are from a two-way unpaired t-test, *P<0.05.
Table 3. Plasma cytokine profile in TRPA1 WT and TRPA1 KO mice
following 14-day infusion of angiotensin II.
14-day angiotensin II
TRPA1 WT TRPA1 KO
Plasma IL-1b (pg mL1) 2.858  1.705
N = 18
2.490  1.600
N = 17
Plasma TNFa (pg mL1) 9.458  2.835
N = 18
8.821  3.144
N = 17
Plasma IL-12 (pg mL1) 273.7  436.3
N = 18
124.5  142.4
N = 17
Plasma KC (pg mL1) 280.8  275.9
N = 18
326.7  323.3
N = 17
Plasma IFNc (pg mL1) 10.13  9.736
N = 18
6.971  5.535
N = 17
Plasma IL-10 (pg mL1) 111.3  91.30
N = 17
76.98  53.82
N = 17
Angiotensin II (1.1 mg kg1 a day for 14 days) was infused via a sub-
cutaneously implanted minipump. Blood was collected at termination
and plasma extracted. Cytokines were measured using a multiplex
ELISA. N as indicated, data shown  SEM.
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Figure 5. IL-6 production in TRPA1 WT and KO mice following 14-day infusion of angiotensin II or in control animals. Angiotensin II
(1.1 mg kg1 a day) was infused for 14 days via a subcutaneously implanted minipump. Control mice received an empty pump. At termination,
blood was collected and plasma extracted. IL-6 was then measured using a multiplex enzyme-linked immunosorbent assay (ELISA) and is shown in
A. N = 8 WT control, 16 WT angiotensin treated, 10 KO control, 17 KO angiotensin treated. mRNA was extracted from aorta and heart tissue
from angiotensin II treated or control TRPA1 WT and KO mice. Following conversion to cDNA, qPCR was used to quantify IL-6 copy numbers
against a standard curve. Average copy numbers are shown in B and C, respectively. N = 2 WT control, 8 WT angiotensin, 3 KO control, 9 KO
angiotensin (B) and 9 WT control, 14 WT angiotensin treated, 10 KO control, 17 KO angiotensin treated (C). Data is presented  SEM and
statistics are from a two-way ANOVA, with Sidak’s post hoc test. *P < 0.05 or **P < 0.01 compared to respective control. #P < 0.05 compared
to WT angiotensin II-treated animals.
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Figure 6. TRPA1 expression in organs involved in the control of BP and locomotion. mRNA was extracted from dorsal root ganglion neurones
(DRG) (A), aorta, heart, mesenteric arterioles (B), and several discrete brain regions (C) from TRPA1 WT and KO mice following 14-day infusion
with angiotensin II (1.1 mg kg1 day1) with a subcutaneously implanted minipump or a control minipump. Following conversion to cDNA,
TRPA1 copy numbers were measured using qPCR. N = 3 WT control, 7 WT angiotensin treated (A and B), 2 KO control, 9 KO angiotensin treated
(A) or N = 3 WT control, and 3 WT angiotensin treated (C). Data is presented  SEM and statistics are from a two-way ANOVA, with all groups
compared with Sidak’s post hoc test. *P < 0.05 compared to respective control.
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TRPA1 KO murine mesenteric arteries from
hypertensive mice show a significant defect
in vasorelaxant capacity to nitric oxide
Although we were unable to isolate a TRPA1- or CGRP-
dependent mechanism within the CA response, there
remains a possibility that TRPA1 may be expressed at
functional levels in mesenteric arteries and may influence
development of the vascular dysfunction associated with
hypertension. In Figure 8 we show mesenteric arteries
from both TRPA1 WT and KO mice demonstrated little
functional deterioration during our acute model of angio-
tensin II-induced hypertension. No alterations in contrac-
tile capacity toward phenylephrine or U46619 were seen,
alongside preserved sensitivity to carbachol-induced
vasorelaxation when compared with normotensive con-
trols (Fig. 8A–C). The only significant change was in the
potency of the nitric oxide (NO) donor SNP, where a
reduced response was observed in TRPA1 KO mesenteric
arteries from hypertensive mice, compared to those from
TRPA1 WT (N=6)
TRPA1 KO (N=5)
(B) (C)(A)
(E) (F)(D)
Figure 7. Vasorelaxation profile of the putative TRPA1 agonist cinnamaldehyde. Mesenteric arterioles from CD1 mice (A–B) or WT and TRPA1 KO
mice (C–F). Vessels were preconstricted with U46619 (10 lmol/L) in order to observe the vasorelaxation response. Concentration-response curves
to CA were constructed in vessels (A) intact or denuded or endothelium, (B) in the presence of HC030031 (50 lmo/L) or vehicle (0.05% v/v
DMSO), and (C) in WT or TRPA1 KO mesenteric arterioles. (D) illustrates the effects of HC030031 (50 lmol/L) or vehicle (0.05% v/v DMSO) in WT
and TRPA1 KO arterioles on CA-induced relaxation, the table below contains the pEC50 and EMax values. (E) shows the effects of CGRP8-37
(3 lmol/L) or vehicle (0.1% v/v of 0.01% BSA in double deionized water) in arterioles collected from WT or TRPA1 KO mice on CGRP-induced
relaxation. (F) shows the effects of CGRP8-37 (3 lmol/L) or vehicle in arterioles collected from WT or TRPA1 KO mice on CA responses. N is
indicated and data is shown  SEM. In (D), *P < 0.05 compared to TRPA1 KO vehicle. pEC50 and EMax from (A–C) analyzed through two-tailed
unpaired t-test, while (D–F) analyzed by two-way ANOVA with Bonferroni’s post hoc test. In (E), ***P < 0.001 compared to TRPA1 WT vehicle,
and ###P < 0.001 compared to TRPA1 KO vehicle.
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normotensive controls (Fig. 8D). There was no difference
in NO sensitivity between vessels from normotensive
TRPA1 WT and KO mice.
Discussion
Our original hypothesis was that cardiovascular phenotype
of TRPA1 KO mice would be altered, producing sensitiv-
ity to hypertension. Investigations using radiotelemetry
effectively showed this was not the case, but unmasked
some surprising findings. A summary of our novel results
is as follows; (1) TRPA1 WT and KO mice displayed
indistinguishable cardiovascular hemodynamics, cardiac
morphology, and function under baseline conditions. (2)
TRPA1 KO mice showed hyperactivity traits. (3) Charac-
teristics of experimental hypertension were broadly similar
in TRPA1 WT and KO mice, suggesting little obvious role
for TRPA1 in systemic BP control in response to angio-
tensin II. (4) Increased hypertrophy, exacerbated physical
activity, and blunted IL-6 production were seen in hyper-
(B)(A)
(D)(C)
Figure 8. Vascular responses in arterioles from hypertensive WT and TRPA1 KO mice. Mesenteric arterioles were collected from saline-treated or
Ang II-treated (1.1 mg kg1 a day for 14 days) WT or TRPA1 KO mice. Concentration-response curves were constructed in response to the
contractile agents phenylephrine (A) and U46619 (B). Vessels were preconstricted with U46619 (10 lmol/L) to observe the relaxation response to
carbachol (C) and SNP (D). N is as indicated and data is presented  SEM. All statistics conducted using a two-way ANOVA with Bonferroni’s
post hoc test. In (D), ***P < 0.001 is compared to TRPA1 KO saline and ##P < 0.01 compared TRPA1 WT Ang II.
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tensive TRPA1 KO mice. (5) TRPA1 receptor expression
in DRG neurons was significantly upregulated during
hypertension. (6) TRPA1 did not have an important role
in CA-induced vasorelaxation. This is in keeping with the
observation of relatively low levels of TRPA1 mRNA
expression in the mesentery. These results suggest a lack
of functional TRPA1 activity in this vascular bed.
In this study, we primarily investigated if TRPA1 dele-
tion would alter cardiovascular phenotype and vulnerabil-
ity to hypertension induced by angiotensin II infusion.
Our findings demonstrate that this is not the case, as
both TRPA1 WT and KO mice developed similar levels of
hypertension in this model. However, a significant and
new finding from this study is of a previously unde-
scribed increase in spontaneous activity and voluntary
exercise in TRPA1 KO mice compared to TRPA1 WT
mice. The mechanisms involved in the control of
voluntary locomotion are currently unclear, but it is likely
that a variety of neuropeptides are involved in central
reward mechanisms. These have been reviewed by Jordan
et al. (2008) and Garland et al. (2011). Several measures
of activity were collected during this study, giving inde-
pendent evaluations of hyperactivity; namely spontaneous
activity, voluntary exercise distance, and running speed.
In all measures, TRPA1 KO mice showed consistent pref-
erences toward increased physical activity, with increased
spontaneous activity counts and wheel running activity,
which was both further and faster than that seen in WT
mice. These differences were exacerbated during hyperten-
sion, where in the latter stages, hypertensive TRPA1 KO
mice showed significantly higher spontaneous activity
counts compared to hypertensive TRPA1 WT mice. It is
known that locomotion control can be a heritable trait in
mice (Swallow et al. 1998) and selective breeding of mice
with a high motivation to run is used to create models of
attention-deficit/hyperactivity disorder (ADHD) (Rhodes
et al. 2005). Several neuropeptides known to be released
downstream of TRPA1 activation in the periphery, such
as substance P, have strong links to mood control when
released centrally (Rotzinger et al. 2010). Locomotive
control is likely to derive from the central nervous sys-
tem; however, significant TRPA1 expression in the brain
was not found in this study. TRPA1 expression occurs in
the developing rat brain (Jo et al. 2013), and is found on
astrocytes from adults, where it has a role in long-term
potentiation (Shigetomi et al. 2013). These findings may
explain the background level of expression we have
detected in our crude brain preparations. It is likely that
selective isolation of discrete brain regions could reveal
precise and functionally important regions of TRPA1
expression, which may influence locomotive behavior.
The precise mechanistic role of TRPA1 in locomotive
control has not been identified; however, increased activ-
ity preferences in TRPA1 KO mice could relate to either a
higher capacity to exercise, through physical muscular
changes, or an altered mental attitude favouring exercise.
Investigations of these possibilities were beyond the scope
of this study but are of significant intrigue, particularly as
the drosophila version of TRPA1 has recently been impli-
cated in centrally derived motor control (Flood et al.
2013).
Hypertension is considered to be a systemic inflamma-
tory disease, characterized by enhanced oxidative stress,
circulating cytokines, and vasculature remodeling, factors
which are associated with faster progression to cardiovas-
cular events and negative disease outcomes (Collier et al.
2011; Touyz and Briones 2011). Using the angiotensin II
model of hypertension, we found TRPA1 to have a lim-
ited ability to modulate hemodynamics, however, some
important differences to the inflammatory profile were
observed. TRPA1 KO mice presented with more substan-
tial cardiac hypertrophy, but blunted ability to increase
IL-6 production; results which are difficult to reconcile.
Hypertrophy is detrimental to the outcome of hyperten-
sion, leading to further increases in BP, inflammation,
and cardiac dysfunction (Hein et al. 2003). By compari-
son, a lower level of IL-6 is suggested to be beneficial,
based on KO studies where IL-6 deletion reduces angio-
tensin II-induced hypertension (Lee et al. 2006) and
where IL-6 is reported to be a marker of diastolic dys-
function and all-cause mortality (Fisman and Tenenbaum
2010). It is likely that angiotensin II infusion leads to an
increase in systemic levels of TRPA1 agonists, including
reactive oxygen species and oxidized proteins (Trevisani
et al. 2007; Andersson et al. 2008). The effect of TRPA1
activation on different cell types is yet to be fully eluci-
dated, but could include alterations in protein expression
profiles or effects on proliferation. Recent studies have
shown TRPA1 agonists to promote cell survival at low
levels (Schaefer et al. 2013), but equally, may inhibit pro-
liferation of melanoma cells (Oehler et al. 2012) and actu-
ally promote pro-proliferation gene expression patterns
within human keratinocytes (Atoyan et al. 2009). Direct
links between TRPA1 activation and cell-specific changes
require further study, but could account for some of the
broader changes noted in this study.
In peripheral tissues, TRPA1 mRNA was predominantly
expressed on DRG neurons, in agreement with previous
findings (Story et al. 2003). A low-level expression was
seen in all vascular tissues investigated. A study by Hatano
et al. (2012) used cultured human synoviocytes and
embryonic kidney cells to show TRPA1 expression can be
induced by transcription factors associated with inflamma-
tion, including nuclear factor kappa B (NFjB) and
hypoxia-inducible factor 1 alpha (HIF1a). In support of
these findings, we show that TRPA1 expression is
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upregulated on DRG neurones from hypertensive mice.
However, data from Hatano et al. (2012) linked increased
TRPA1 expression with inhibition of inflammatory cyto-
kine production, which opposes our findings of similar
cytokine profiles in hypertensive mice and a blunted ability
to produce IL-6 in TRPA1 KO mice. Therefore, we suggest
that TRPA1 may have multiple roles in inflammation
which may be situation specific and deserve further study.
Several studies have investigated TRPA1-induced
vasoreactivity, frequently finding this to be neuropeptide
dependent (Bodkin and Brain 2010). Undoubtedly,
TRPA1 agonists can mediate increased cutaneous blood
flow in a neuropeptide-dependent manner (Graepel et al.
2011). We recently reported CA-induced vasorelaxation
in mesenteric arterioles to be significantly reduced in
TRPA1 KO mice (Pozsgai et al. 2010). In this current
study, a trend toward reduced relaxation in KO mice was
observed, but this did not reach significance. Further-
more, as neither a TRPA1 or CGRP antagonist affected
the CA response, we suggest that TRPA1 may not have a
strong ability to modulate blood flow in the mesenteric
vascular bed, and that these findings may be relevant to
the lack of BP phenotype in TRPA1 KO mice. The ability
and mechanism of TRPA1 to induced vasorelaxation may
be tissue specific, since TRPA1 expression has been found
on endothelial cells in the cerebral artery of rats, inducing
hyperpolarization and vasorelaxation of the underlying
smooth muscle via myoendothelial gap junctions (Earley
et al. 2009). This mechanism cannot feature in the mes-
enteric bed, as our findings show that CA-induced vasore-
laxation was endothelial independent. It remains possible
that CA is not activating TRPA1 in our model, despite its
established role as a TRPA1 agonist. However, we are also
unable to isolate a TRPA1-dependent response in the
mesenteric arteriole using other proven TRPA1 agonists,
including mustard oil (Earley et al. 2009) and PF-
4840154 (Ryckmans et al. 2011) (Data not shown).
Therefore, our current evidence suggests that there is a
limited TRPA1-dependent vasoreactive response in mur-
ine mesenteric arterioles.
We proceeded to investigate the impact of hypertension
on the vasoactive function of mouse mesenteric arterioles.
Several studies have suggested that prolonged hyperten-
sion is associated with the development of endothelial
dysfunction (Konishi and Su 1983; Taddei et al. 1995;
Davel et al. 2011) and that this may be an independent
risk factor for the susceptibility to cardiovascular events
(Sch€achinger et al. 2000). Here, few changes in the con-
tractile or relaxant ability of mesenteric arterioles from
hypertensive mice were seen compared to normotensive
controls. Relaxation in response to carbachol, an acetyl-
choline mimetic, remained unchanged and suggests the
presence of healthy endothelium. A reduced potency of
the NO donor SNP was observed in vessels from hyper-
tensive TRPA1 KO mice compared to vessels from nor-
motensive TRPA1 KO mice, but the relevance of this is
not currently known. It is possible that signaling changes,
reactive oxygen species, and vascular hypertrophy may
have roles in this finding. Alongside our results showing
increased TRPA1 mRNA expression in DRG from hyper-
tensive mice, these findings indicate a more prominent
role for TRPA1 in the control of BP and inflammation
could develop in scenarios with prolonged hypertension.
Conclusions
Conscious and unrestrained TRPA1 WT and KO mice
displayed similar basal hemodynamics, cardiac morphol-
ogy, and function. Comparable hypertensive responses to
angiotensin II infusion were noted in both genotypes, but
hypertensive TRPA1 KO mice showed blunted production
of IL-6 and increased cardiac hypertrophy compared to
WT mice. Both IL-6 production and cardiac hypertrophy
have notable links to the prevalence of cardiovascular
events and morbidity. We found little ability for TRPA1
to modulate vascular tone in arterioles from the mesen-
teric bed under basal or hypertensive conditions. Most
strikingly, our results reveal a novel role for TRPA1 in
controlling physical activity in vivo, where TRPA1 KO
mice showed a preference for increased locomotion and
physical exercise, which was exacerbated during hyperten-
sion. These findings emphasize the importance of studies
investigating the interplay between inflammatory disease
and physical activity.
Acknowledgements
The authors thank Patrick Fox for advice. This study was
supported by the British Heart Foundation (J. V. B., P.
T., M. N., M. J. S.), a capacity building award in Integra-
tive Mammalian Biology funded by the BBSRC, BPS,
HEFCE, KTN, MRC, and SFC (A. A. A., L. L., S. D. B.)
and Arthritis Research UK (E. S. F.).
Disclosures
None declared.
References
Andersson DA, Gentry C, Moss S, Bevan S (2008). Transient
receptor potential A1 is a sensory receptor for multiple
products of oxidative stress. J Neurosci 28: 2485–2494.
Atoyan R, Shander D, Botchkareva NV (2009). Non-neuronal
expression of transient receptor potential type A1 (TRPA1) in
human skin. J Invest Dermatol 129: 2312–2315.
2014 | Vol. 2 | Iss. 4 | e00052
Page 14
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
TRPA1 in Cardiovascular Health and Locomotive Control J. V. Bodkin et al.
Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR,
Petrus MJ, et al. (2004). Noxious cold ion channel TRPA1 is
activated by pungent compounds and bradykinin. Neuron 41:
849–857.
Bodkin JV, Brain SD (2010). Transient receptor potential
ankyrin 1: emerging pharmacology and indications for
cardiovascular biology. Acta Physiol (Oxf) 15: 1748–1716.
Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, et al.
(2011). Can emerging biomarkers of myocardial remodelling
identify asymptomatic hypertensive patients at risk for
diastolic dysfunction and diastolic heart failure? Eur J Heart
Fail 13: 1087–1095.
Davel AP, Wenceslau CF, Akamine EH, Xavier FE, Couto GK,
Oliveira HT, et al. (2011). Endothelial dysfunction in
cardiovascular and endocrine-metabolic diseases: an update.
Braz J Med Biol Res 44: 920–932.
Earley S (2012). TRPA1 channels in the vasculature. Br J
Pharmacol 167: 13–22.
Earley S, Gonzales AL, Crnich R (2009).
Endothelium-dependent cerebral artery dilation mediated by
TRPA1 and Ca2+-activated K+ channels. Circ Res 104:
987–994.
Fernandes ES, Russell FA, Spina D, McDougall JJ, Graepel R,
Gentry C, et al. (2011). A distinct role for transient receptor
potential ankyrin 1, in addition to transient receptor potential
vanilloid 1, in tumor necrosis factor a-induced inflammatory
hyperalgesia and Freund’s complete adjuvant-induced
monarthritis. Arthritis Rheum 63: 819–829.
Fisman EZ, Tenenbaum A (2010). The ubiquitous
interleukin-6: a time for reappraisal. Cardiovasc Diabetol 9: 62.
Flood TF, Gorczyca M, White BH, Ito K, Yoshihara M, 2013.
A large-scale behavioral screen to identify neurons controlling
motor programs in the Drosophila brain. G3 (Bethesda)
3:1629–1637.
Frederick J, Buck ME, Matson DJ, Cortright DN (2007).
Increased TRPA1, TRPM8, and TRPV2 expression in dorsal
root ganglia by nerve injury. Biochem Biophys Res Commun
358: 1058–1064.
Garland T, Schutz H, Chappell MA, Keeney BK, Meek TH,
Copes LE, et al. (2011). The biological control of voluntary
exercise, spontaneous physical activity and daily energy
expenditure in relation to obesity: human and rodent
perspectives. J Exp Biol 214: 206–229.
Graepel R, Fernandes ES, Aubdool AA, Andersson DA, Bevan
S, Brain SD (2011). 4-oxo-2-nonenal (4-ONE): evidence of
transient receptor potential ankyrin 1-dependent and
-independent nociceptive and vasoactive responses in vivo. J
Pharmacol Exp Ther 337: 117–124.
Grant AD, Pinter E, Salmon A-ML, Brain SD (2005). An
examination of neurogenic mechanisms involved in mustard
oil-induced inflammation in the mouse. Eur J Pharmacol 507:
273–280.
Harada M, Yano S, Hirayama Y, Yamazaki R (1975).
Pharmacological studies on Chinese cinammon. II. Effects of
cinnamaldehyde on the cardiovascular and digestive systems.
Chem Pharm Bull (Tokyo) 23: 941–947.
Harada M, Hirayama Y, Yamazaki R (1982). Pharmacological
studies on Chinese cinnamon. V. Catecholamine releasing
effect of cinnamaldehyde in dogs. J Pharmacobiodyn 5: 539–
546.
Hatano N, Itoh Y, Suzuki H, Muraki Y, Hayashi H,
Onozaki K, et al. (2012). Hypoxia-inducible factor-1a
(HIF1a) switches on transient receptor potential ankyrin
repeat 1 (TRPA1) gene expression via a hypoxia response
element-like motif to modulate cytokine release. J Biol Chem
287: 31962–31972.
Hazari MS, Haykal-Coates N, Winsett DW, Krantz QT, King
C, Costa DL, et al. (2011). TRPA1 and sympathetic activation
contribute to increased risk of triggered cardiac arrhythmias in
hypertensive rats exposed to diesel exhaust. Environ Health
Perspect 119: 951–957.
Hein S, Arnon E, Kostin S, Sch€onburg M, Els€asser A,
Polyakova V, et al. (2003). Progression from compensated
hypertrophy to failure in the pressure-overloaded human
heart. Circulation 107: 984–991.
Hikiji A, Yamamoto H, Sunakawa M, Suda H (2000).
Increased blood flow and nerve firing in the cat canine tooth
in response to stimulation of the second premolar pulp. Arch
Oral Biol 45: 53–61.
Iwasaki Y, Tanabe M, Kobata K, Watanabe T (2008). TRPA1
agonists-allyl isothiocyanate and cinnamaldehyde-induce
adrenaline secretion. Biosci Biotechnol Biochem 72:
2608–2614.
Jaquemar D, Schenker T, Trueb B (1999). An ankyrin-like
protein with transmembrane domains is specifically lost after
oncogenic transformation of human fibroblasts. J Biol Chem
274: 7325–7333.
Jo KD, Lee KS, Lee WT, Hur MS, Kim HJ (2013).
Expression of transient receptor potential channels in the
ependymal cells of the developing rat brain. Anat Cell Biol
46: 68–78.
Jordan LM, Liu J, Hedlund PB, Akay T, Pearson KG (2008).
Descending command systems for the initiation of locomotion
in mammals. Brain Res Rev 57: 183–191.
Konishi M, Su C (1983). Role of endothelium in dilator
responses of spontaneously hypertensive rat arteries.
Hypertension 5: 881–886.
Kunkler PE, Ballard CJ, Oxford GS, Hurley JH (2011). TRPA1
receptors mediate environmental irritant-induced meningeal
vasodilatation. Pain 152: 38–44.
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
2014 | Vol. 2 | Iss. 4 | e00052
Page 15
J. V. Bodkin et al. TRPA1 in Cardiovascular Health and Locomotive Control
Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C,
Pollock JS, et al. (2006). Angiotensin II hypertension is
attenuated in interleukin-6 knockout mice. Am J Physiol Heart
Circ Physiol 290: H935–H940.
Louis SM, Jamieson A, Russell NJ, Dockray GJ (1989). The
role of substance P and calcitonin gene-related peptide in
neurogenic plasma extravasation and vasodilatation in the rat.
Neuroscience 32: 581–586.
Marshall NJ, Liang L, Bodkin J, Dessapt-Baradez C, Nandi M,
Collot-Teixeira S, et al. (2013). A role for TRPV1 in
influencing the onset of cardiovascular disease in obesity.
Hypertension 61: 246–252.
Melendez GC, McLarty JL, Levick SP, Du Y, Janicki JS, Brower
GL (2010). Interleukin 6 mediates myocardial fibrosis,
concentric hypertrophy, and diastolic dysfunction in rats.
Hypertension 56: 225–231.
Morris JB, Stanek J, Gianutsos G (1999). Sensory
nerve-mediated immediate nasal responses to inspired acrolein.
J Appl Physiol 87: 1877–1886.
Namer B, Seifert F, Handwerker H, Maihofner C (2005).
TRPA1 and TRPM8 activation in humans: effects of
cinnamaldehyde and menthol. NeuroReport 16: 955–999.
Oehler B, Scholze A, Schaefer M, Hill K (2012). TRPA1 is
functionally expressed in melanoma cells but is not critical for
impaired proliferation caused by allyl isothiocyanate or
cinnamaldehyde. Naunyn Schmiedebergs Arch Pharmacol 385:
555–563.
Pedersen BK, Febbraio MA (2008). Muscle as an endocrine
organ: focus on muscle-derived interleukin-6. Physiol Rev 88:
1379–1406.
Pozsgai G, Bodkin JV, Graepel R, Bevan S, Andersson DA,
Brain SD (2010). Evidence for the pathophysiological relevance
of TRPA1 receptors in the cardiovascular system in vivo.
Cardiovasc Res 87: 760–768.
Pozsgai G, Hajna Z, Bagoly T, Boros M, Kemeny A, Materazzi
S, et al. (2012). The role of transient receptor potential
ankyrin 1 (TRPA1) receptor activation in
hydrogen-sulphide-induced CGRP-release and vasodilation.
Eur J Pharmacol 689: 56–64.
Respress JL, Wehrens XHT (2010). Transthoracic
echocardiography in mice. J Vis Exp 28: pii: 1738.
Rhodes JS, Gammie SC, Garland T (2005). Neurobiology of
Mice Selected for High Voluntary Wheel-running Activity.
Integr Comp Biol 45: 438–455.
Rotzinger S, Lovejoy DA, Tan LA (2010). Behavioral effects of
neuropeptides in rodent models of depression and anxiety.
Peptides 31: 736–756.
Russell FA, Fernandes ES, Courade J-P, Keeble JE, Brain SD
(2009). Tumour necrosis factor a mediates transient receptor
potential vanilloid 1-dependent bilateral thermal hyperalgesia
with distinct peripheral roles of interleukin-1b, protein kinase
C and cyclooxygenase-2 signalling. Pain 142: 264–274.
Ryckmans T, Aubdool AA, Bodkin JV, Cox P, Brain SD,
Dupont T, et al. (2011). Design and pharmacological
evaluation of PF-4840154, a non-electrophilic reference agonist
of the TrpA1 channel. Bioorg Med Chem Lett 21: 4857–4859.
Savoia C, Schiffrin EL (2006). Inflammation in hypertension.
Curr Opin Nephrol Hypertens 15: 152–158.
Sch€achinger V, Britten MB, Zeiher AM (2000). Prognostic
impact of coronary vasodilator dysfunction on adverse
long-term outcome of coronary heart disease. Circulation 101:
1899–1906.
Schaefer EA, Stohr S, Meister M, Aigner A, Gudermann T,
Buech TR (2013). Stimulation of the chemosensory TRPA1
cation channel by volatile toxic substances promotes cell
survival of small cell lung cancer cells. Biochem Pharmacol 85:
426–438.
Shigetomi E, Jackson-Weaver O, Huckstepp RT, O’Dell TJ,
Khakh BS (2013). TRPA1 channels are regulators of astrocyte
basal calcium levels and long-term potentiation via
constitutive D-serine release. J Neurosci 33: 10143–10153.
Smillie S-J, King R, Kodji X, Outzen E, Pozsgai G, Fernandes
E, et al. (2014). An ongoing role of a-calcitonin gene-related
peptide as part of a protective network against hypertension,
vascular hypertrophy, and oxidative stress. Hypertension 63:
1056–1062.
Story G, Peier A, Reeve A, Eid S, Mosbacher J, Hricik T, et al.
(2003). ANKTM1, a TRP-like channel expressed in nociceptive
neurons, is activated by cold temperatures. Cell 112: 819–829.
Swallow JG, Carter PA, Garland T Jr (1998). Artificial selection
for increased wheel-running behavior in house mice. Behav
Genet 28: 227–237.
Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo
CB, et al. (1995). Aging and endothelial function in
normotensive subjects and patients with essential hypertension.
Circulation 91: 1981–1987.
Touyz RM, Briones AM (2011). Reactive oxygen species and
vascular biology: implications in human hypertension.
Hypertens Res 34: 5–14.
Trevisani M, Siemens J, Materazzi S, Bautista DM, Nassini R,
Campi B, et al. (2007). 4-Hydroxynonenal, an endogenous
aldehyde, causes pain and neurogenic inflammation through
activation of the irritant receptor TRPA1. Proc Natl Acad Sci
USA 104: 13519–13524.
VanderEnde DS, Morrow JD (2001). Release of markedly
increased quantities of prostaglandin D2 from the skin in vivo
in humans after the application of cinnamic aldehyde. J Am
Acad Dermatol 45: 62–67.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N,
De Paepe A, et al. (2002). Accurate normalization of real-time
2014 | Vol. 2 | Iss. 4 | e00052
Page 16
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
TRPA1 in Cardiovascular Health and Locomotive Control J. V. Bodkin et al.
quantitative RT-PCR data by geometric averaging of multiple
internal control genes. Genome Biol 3: RESEARCH0034.
Xue YL, Shi HX, Murad F, Bian K (2011). Vasodilatory effects
of cinnamaldehyde and its mechanism of action in the rat
aorta. Vasc Health Risk Manag 7: 273–280.
Yanaga A, Goto H, Nakagawa T, Hikiami H, Shibahara N,
Shimada Y (2006). Cinnamaldehyde induces
endothelium-dependent and -independent vasorelaxant action
on isolated rat aorta. Biol Pharm Bull 29:2415–2418.
ª 2014 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
2014 | Vol. 2 | Iss. 4 | e00052
Page 17
J. V. Bodkin et al. TRPA1 in Cardiovascular Health and Locomotive Control
